Takeda Vaccines, Inc., a subsidiary of Takeda Pharmaceutical Co., Ltd., is an American company located in Bozeman, MT. The firm provides biological research and development services.

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology. The company is headquartered in Gaithersburg, Maryland

NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its EnPC®, the drug delivery technology based on a natural derived protein capsule. In addition to advancing its proprietary pipeline, the company aims to be a partner of choice in particular for antibody and mRNA drug developers stymied by the hurdles of delivering these and other drug modalities into the brain and CNS tissue. Operating as a drug developer and a delivery expert, NEUWAY will demonstrate the value of its technology through its internal orphan neurological disease pipeline and partnered programs.

Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland.

Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

The Institut national de la recherche agronomique (INRA, pronounced [inʁa]; English: National Institute of Agricultural Research) is a French public research institute dedicated to agricultural science. It was founded in 1946 and is a Public Scientific and Technical Research Establishment under the joint authority of the Ministries of Research and Agriculture.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Beijing Wantai is a manufacturer of infectious disease diagnostics. It operates domestic and international diagnostic test businesses in the fields of human infectious diseases and screening of blood donors. Its customers are blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. Innovax is a separate division of Wantai that focuses on the development and commercialization of recombinant vaccines. Innovax's flagship product Hecolin, is the world's first launched Hepatitis E vaccine. Its production facilities are GMP, ISO9001 and ISO13485 certified. Founded in 1991, Beijing Wantai is headquartered in Beijing, China.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Cambridge Technologies LLC engages in developing bovine and swine diagnostics. Its primary product, Precision Vaccinology, helps veterinarians to find solutions to herd health problems. The company was founded by Wayne Freese and Randy Simonson and is headquartered in Worthington, MN.

Wuhan Huajiyuan Biotechnology Development Co., Ltd., established on 2013-06-05, Business scope includes biotechnology development.(Projects with special national regulations shall be operated within the approved period after approval or with a license)

Merck Sharp & Dohme LLC, part of Merck & Co., Inc., is a company headquartered in Kenilworth, NJ, that operates as a pharmaceutical company.

Xiamen Innovax Biotech Co., Ltd. manufactures vaccines and diagnostic reagents. It focuses on research and development, manufacturing, marketing of vaccine, diagnosis kit and medical equipment. The company was founded in 2005 and is headquartered in Xiamen, China.

Jiaxing Zhuoshi Biotechnology Co., Ltd., established on 2018-08-17, Business scope includes biotechnology,network technology,Technology development in the field of medical technology,technical consulting,Technical Services,technology transfer;Medical information consultation(Does not include medical services);Medical device information consultation;Corporate Image Planning;Business Management Consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)